Other Manufacturing. In connection with any other manufacturing and supply of Compound and/or Product, INDEVUS will consider AVENTIS in priority to any Third Party, as such manufacturer and supplier.
Other Manufacturing. There are major idle production facilities throughout the country. As in agriculture, output from these facilities ten years ago was enormous and they employed thousands. In the case of many of these operations, the collapse of the Soviet system means permanent disappearance of markets. At the same time, however, domestic and regional markets for certain product lines can be identified, and equipment to revive production and exploit these market opportunities can be renovated. Production may be only a fraction of its former level, but this is far better than facilities sitting idle as they are now, and it creates the basis for the emergence of new businesses. Table below gives an indication of the kinds of products that were produced in volume in the country ten years ago, showing dramatic production declines. This is followed by a focus on certain manufacturing sectors more likely to be viable. The total value of the 1990 production volumes of the products in Table was over $2 billion, while at today’s production the total comes to less than $100 million. Some of these products lines are dominated by global firms with production somewhere in the region, so that they are unlikely to be competitive if restarted, including tires, detergent, cardboard, refrigerators and stoves, air conditioners, and bicycles. Having said this, during the privatization process there may be certain production units that would be considered worth picking up by global brand producers in order to better service the local market with their brand names, for example in air conditioners, white goods, tires, or detergent. These businesses would not be the target of a business development program; their viability would be determined by foreign strategic investors through the privatization process.
Other Manufacturing. In connection with any other manufacturing and supply of Compound and/or Product, INDEVUS will consider AVENTIS in priority to any Third Party, as such manufacturer and supplier. If you are in agreement with these changes, please acknowledge by having this letter signed by an authorized member of your company. Best regards, For Novexel S.A. For Indevus Pharmaceuticals Inc. /s/ Xxxx Xxxxxxxx /s/ Xxxxx X. Xxxxxx, M.D. Name: Xxxx Xxxxxxxx Name: Xxxxx X. Xxxxxx, M.D. Title: CEO Title: Chairman and Chief Executive Officer Date: Date: for Aventis Pharma SA for Aventis Pharma SA /s/ Xxxx-Xxx Xxxxxx /s/ Xxxx Xxxxxx Name: Xxxx-Xxx Xxxxxx Name: Xxxx Xxxxxx Title: President & CEO Title: VP, Legal Operations Date: Date: This Termination Agreement (“Termination Agreement”) is executed, delivered, and effective on this 4th day of December 2006 (the “Effective Date”) by and between Indevus Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 00 Xxxxxx Xxxxxx, Xxxxxxxxx, Xxxxxxxxxxxxx 00000, Xxxxxx Xxxxxx (“Indevus”), and Novexel SA, a corporation organized and existing under the laws of France and having its principal office at Parc Biocitech, 000, xxxxx xx Xxxxx, X-00000 Xxxxxxxxxxx, Xxxxxx (“Novexel”). Indevus and Novexel may be referred to herein individually as a “Party” or collectively as the “Parties.”
Other Manufacturing. Except as provided herein a party developing a Product shall have the right, in its sole discretion, to have such Product manufactured by third parties or to manufacture such Product itself.
Other Manufacturing. (1) LICENSEE shall, at its election, have the right to manufacture STUDY PRODUCT and/or HCT STUDY PRODUCT for use under this AGREEMENT at any site and at any time it deems appropriate. At LICENSEE’s request and if agreed by [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. UTMDACC and provided that UTMDACC has the existing ability, capacity, facilities, equipment, resources, and expertise to do so, giving reasonable priority to the use of its resources for the manufacturing of HCT STUDY PRODUCT for use in the RESEARCH PROGRAM in such determination, UTMDACC will manufacture (including formulating and/or assembling) and supply STUDY PRODUCT (other than the HCT STUDY PRODUCT) on behalf of LICENSEE, and such manufacturing and supply shall be subject to the terms and conditions to be agreed by the parties.
(2) UTMDACC agrees to reasonably assist LICENSEE in the establishment of manufacturing facilities for LICENSEE and, at LICENSEE’s request and cost, shall deliver to LICENSEE (or its designee), all data, reports, standard operating procedures, analyses, reagents, vectors, cell lines (such as feeder cells) and other information directly relating to the manufacture of HCT STUDY PRODUCTS that exists at UTMDACC and is then reasonably available and transferable, subject to any third party confidentiality obligations. If at any time during the TERM, LICENSEE identifies particular documents, data or information directly relating to the manufacture of HCT STUDY PRODUCTS that exists at UTMDACC, is then owned or licensed by LICENSEE, and is reasonably available and transferable and that was not previously delivered to LICENSEE, UTMDACC shall promptly provide such data and information to LICENSEE subject to any third party confidentiality obligations, upon LICENSEE’s request and expense, and such expense shall be included in the DEVELOPMENT COSTS and funded by ZIOPHARM in accordance with Section 5. As applicable with good practices, the transfer of biologic materials and vectors shall be by the use of qualified shippers.
Other Manufacturing. (a) Juno shall, at its election, have the right to manufacture Licensed Products for use in the Collaboration at any site it deems appropriate.
(b) FHCRC agrees to assist Juno in the establishment of manufacturing facilities for [***] and, at Juno’s request, shall deliver to Juno (or its designee), all data, reports, analyses and other information relating to the manufacture of HCT Study Products that exists at FHCRC, is then owned or licensed by Juno, and is then reasonably available and transferable in a tangible form. If at any time during the Term, Juno identifies particular documents, data or information that exists at FHCRC, is then owned or licensed by Juno, and is reasonably available and transferable in a tangible form as of the Effective Date and that was not previously delivered to Juno, FHCRC shall promptly provide such data and information to Juno, upon Juno’s request. Juno shall reimburse FHCRC for [***] by FHCRC in complying with this Section 5.5(b), and FHCRC fees for assistance with establishment of manufacturing facilities shall be agreed pursuant to applicable Project Agreements.
(c) FHCRC shall provide Juno with reasonable access, at agreed times during ordinary business hours, to FHCRC personnel knowledgeable regarding the manufacture of HCT Study Products for the purpose of assisting Juno with technology transfer to a manufacturing facility. The assistance may be rendered by teleconference or in-person meetings, at Juno’s expense, and FHCRC fees for such assistance shall be agreed pursuant to applicable Project Agreements.
Other Manufacturing. Subject to Section 6.4 (Partner’s Ability to Become a Second Manufacturing Source), Epirus shall supply, [***], to Partner such quantities of Licensed Product necessary for Partner’s use in Commercializing the Licensed Product in the Territory at a price equal to [***], provided, however, that, in respect of the initial three (3) Licensed Products, Partner shall be Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. entitled to [***]for Commercialization of such Licensed Product in the Territory [***]. Subject to the foregoing and to Section 6.4 (Partner’s Ability to Become a Second Manufacturing Source), Partner shall not obtain Licensed Product from any source other than Epirus (or with Epirus’s permission, Epirus’s Third Party CMO) without the approval of the JMC, which shall not be unreasonably withheld. To the extent necessary to comply with Applicable Law, or as otherwise determined by the JMC (and, in any event, no later than [***] prior to initial Regulatory Approval submission for each Product), Epirus and Partner shall enter into one or more supply agreements on reasonable and customary terms, consistent with the terms hereunder, governing the supply of each Licensed Product from Epirus to Partner, and/or from Partner to Epirus in the event Partner would become a Manufacturing source for any of the Licensed Products in accordance with the terms hereof.
